Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Drug

Sinocelltech’s SCTV01E Vaccine Receives NMPA Approval for Phase II Study

Fineline Cube Nov 11, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received approval from the...

Company Drug

3SBio’s Thrombopoietin Study in Pediatric ITP Reaches Primary Endpoint

Fineline Cube Nov 10, 2022

China-based 3SBio Inc. (HKG: 1530) has announced that its multi-center, randomized, double-blind, placebo-controlled study assessing...

Company Deals

Zenas BioPharma Completes $118M Series B Financing to Advance Obexelimab

Fineline Cube Nov 10, 2022

Autoimmune disease drug developer Zenas BioPharma, which is based in the US and China, has...

Company Drug

LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China

Fineline Cube Nov 10, 2022

Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study...

Company Deals

Innovex Medical Files for IPO in Hong Kong to Boost Product Development

Fineline Cube Nov 10, 2022

Innovex Medical Co., Ltd, a non-vascular interventional surgery solutions provider based in Shanghai, has filed...

Company Drug

NMPA Conditionally Approves Yingli Pharma’s Linperlisib for Lymphoma

Fineline Cube Nov 10, 2022

The National Medical Products Administration (NMPA) website indicates that linperlisib, a Category 1 anti-tumor drug,...

Company Drug

Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918

Fineline Cube Nov 10, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center...

Policy / Regulatory

China Releases 14th Five-Year Plan for National Health Informatization

Fineline Cube Nov 10, 2022

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and the National Bureau...

Company

Zai Lab Reports 33% YOY Revenue Growth in Q3 2022

Fineline Cube Nov 10, 2022

Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q3 2022 earnings...

Company Deals

GSK Partners with CASPC to Advance HIV Sustained Care Advocacy in China

Fineline Cube Nov 10, 2022

The 5th China International Import Expo (CIIE) saw the unveiling of a partnership between GlaxoSmithKline...

Company Drug

3SBio Receives NMPA Review for Pediatric ITP Thrombopoietin Filing

Fineline Cube Nov 10, 2022

China-based 3SBio Inc. (HKG: 1530) has announced that the National Medical Products Administration (NMPA) has...

Company Deals

Boston Scientific Partners with Omron for Atrial Fibrillation Management

Fineline Cube Nov 10, 2022

US-based Boston Scientific Corporation (NYSE: BSX) has announced a partnership with Japan-based Omron Healthcare at...

Company Deals

Takeda Partners with AWS and Accenture to Launch Innovation Incubator at CIIE

Fineline Cube Nov 10, 2022

The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Takeda...

Company Drug

Betta Pharmaceuticals’ BPI-D0316 Shows Promise in Phase II/III Lung Cancer Study

Fineline Cube Nov 10, 2022

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced the summary report of a Phase...

Company

BeiGene Reports 88% YOY Revenue Growth in Q3 2022

Fineline Cube Nov 10, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) released its Q3 2022 earnings...

Company Deals

Shandong Xinhua and Bayer Announce Strategic Partnership at CIIE

Fineline Cube Nov 9, 2022

A strategic partnership between China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) and Bayer Consumer...

Company Deals

Medtronic Partners with Shanghai JiaHui Hospital at CIIE

Fineline Cube Nov 9, 2022

US-based Medtronic Inc. (NYSE: MDT) has announced a partnership with Shanghai JiaHui International Hospital, unveiled...

Company Deals

ChainGen Bio Raises RMB 45M in Angel Round for X-oligo Conjugates Development

Fineline Cube Nov 9, 2022

ChainGen Bio, a Shanghai-based developer of X-oligo conjugates (XOCs), has reportedly raised RMB 45 million...

Company Deals

Yibao Technology Secures Series A+ Funding to Expand Health Insurance Services

Fineline Cube Nov 9, 2022

Yibao Technology Co., Ltd, a Shanghai-based service provider for city-level supplementary commercial insurance (“Huiminbao”) schemes,...

Company Drug

Haisco’s HSK16149 Accepted for Review by NMPA for Diabetic Neuropathic Pain

Fineline Cube Nov 9, 2022

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that a market approval filing...

Posts pagination

1 … 654 655 656 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.